Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss
CAMBRIDGE, England & TOKYO–(BUSINESS WIRE)–Mogrify Limited (CEO: Darrin M. Disley, Ph.D., “Mogrify®”), a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), a leader in regenerative medicine, today announced that they have executed a collaborative … [Read more…]
